These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 26646680)

  • 1. Unintended Pregnancies Observed With Combined Use of the Levonorgestrel Contraceptive Implant and Efavirenz-based Antiretroviral Therapy: A Three-Arm Pharmacokinetic Evaluation Over 48 Weeks.
    Scarsi KK; Darin KM; Nakalema S; Back DJ; Byakika-Kibwika P; Else LJ; Dilly Penchala S; Buzibye A; Cohn SE; Merry C; Lamorde M
    Clin Infect Dis; 2016 Mar; 62(6):675-682. PubMed ID: 26646680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efavirenz decreases etonogestrel exposure: a pharmacokinetic evaluation of implantable contraception with antiretroviral therapy.
    Chappell CA; Lamorde M; Nakalema S; Chen BA; Mackline H; Riddler SA; Cohn SE; Darin KM; Achilles SL; Scarsi KK
    AIDS; 2017 Sep; 31(14):1965-1972. PubMed ID: 28692531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Physiologically based pharmacokinetic modelling prediction of the effects of dose adjustment in drug-drug interactions between levonorgestrel contraceptive implants and efavirenz-based ART.
    Roberts O; Rajoli RKR; Back DJ; Owen A; Darin KM; Fletcher CV; Lamorde M; Scarsi KK; Siccardi M
    J Antimicrob Chemother; 2018 Apr; 73(4):1004-1012. PubMed ID: 29365101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of double-dose levonorgestrel subdermal implant in women taking efavirenz-based antiretroviral therapy: The DoubLNG pharmacokinetic study.
    Cirrincione LR; Nakalema S; Chappell CA; Byakika-Kibwika P; Kyohairwe I; Winchester L; Mackline H; Pham MM; Cohn SE; Siccardi M; Owen A; Fletcher CV; Lamorde M; Scarsi KK
    Contraception; 2023 Jun; 122():109975. PubMed ID: 36787829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nevirapine- versus Efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and Tuberculosis infections in India: a multi-centre study.
    Sinha S; Gupta K; Tripathy S; Dhooria S; Ranjan S; Pandey RM
    BMC Infect Dis; 2017 Dec; 17(1):761. PubMed ID: 29228918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pharmacokinetic and pharmacogenetic evaluation of contraceptive implants and antiretroviral therapy among women in Kenya and Uganda.
    Patel RC; Stalter RM; Thomas KK; Tamraz B; Blue SW; Erikson DW; Kim CJ; Kelly EJ; Nanda K; Kourtis AP; Lingappa JR; Mugo N; Baeten JM; Scarsi KK;
    AIDS; 2019 Nov; 33(13):1995-2004. PubMed ID: 31306173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Effect of Gene Variants on Levonorgestrel Pharmacokinetics When Combined With Antiretroviral Therapy Containing Efavirenz or Nevirapine.
    Neary M; Lamorde M; Olagunju A; Darin KM; Merry C; Byakika-Kibwika P; Back DJ; Siccardi M; Owen A; Scarsi KK
    Clin Pharmacol Ther; 2017 Sep; 102(3):529-536. PubMed ID: 28187506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiretroviral therapy and vaginally administered contraceptive hormones: a three-arm, pharmacokinetic study.
    Scarsi KK; Cramer YS; Rosenkranz SL; Aweeka F; Berzins B; Coombs RW; Coughlin K; Moran LE; Zorrilla CD; Akelo V; Aziz M; Friedman RK; Gingrich D; Swaminathan S; Godfrey C; Cohn SE;
    Lancet HIV; 2019 Sep; 6(9):e601-e612. PubMed ID: 31498109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study.
    Manosuthi W; Sungkanuparph S; Tantanathip P; Lueangniyomkul A; Mankatitham W; Prasithsirskul W; Burapatarawong S; Thongyen S; Likanonsakul S; Thawornwa U; Prommool V; Ruxrungtham K;
    Clin Infect Dis; 2009 Jun; 48(12):1752-9. PubMed ID: 19438397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contraceptive implant use duration is not associated with breakthrough pregnancy among women living with HIV and using efavirenz: a retrospective, longitudinal analysis.
    Stalter RM; Amorim G; Mocello AR; Jakait B; Shepherd BE; Musick B; Bernard C; Bukusi EA; Wools-Kaloustian K; Cohen CR; Yiannoutsos CT; Patel RC;
    J Int AIDS Soc; 2022 Sep; 25(9):e26001. PubMed ID: 36073977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efavirenz versus nevirapine-based initial treatment of HIV infection: clinical and virological outcomes in Southern African adults.
    Nachega JB; Hislop M; Dowdy DW; Gallant JE; Chaisson RE; Regensberg L; Maartens G
    AIDS; 2008 Oct; 22(16):2117-25. PubMed ID: 18832875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy.
    Boulle A; Van Cutsem G; Cohen K; Hilderbrand K; Mathee S; Abrahams M; Goemaere E; Coetzee D; Maartens G
    JAMA; 2008 Aug; 300(5):530-9. PubMed ID: 18677025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pregnancy rates in HIV-positive women using contraceptives and efavirenz-based or nevirapine-based antiretroviral therapy in Kenya: a retrospective cohort study.
    Patel RC; Onono M; Gandhi M; Blat C; Hagey J; Shade SB; Vittinghoff E; Bukusi EA; Newmann SJ; Cohen CR
    Lancet HIV; 2015 Nov; 2(11):e474-82. PubMed ID: 26520927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Efavirenz-, Ritonavir-Boosted Lopinavir-, and Nevirapine-Based Antiretroviral Regimens on the Pharmacokinetics of Lumefantrine and Safety of Artemether-Lumefantrine in Plasmodium falciparum-Negative HIV-Infected Malawian Adults Stabilized on Antiretroviral Therapy.
    Banda CG; Dzinjalamala F; Mukaka M; Mallewa J; Maiden V; Terlouw DJ; Lalloo DG; Khoo SH; Mwapasa V
    Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30150465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concomitant contraceptive implant and efavirenz use in women living with HIV: perspectives on current evidence and policy implications for family planning and HIV treatment guidelines.
    Patel RC; Morroni C; Scarsi KK; Sripipatana T; Kiarie J; Cohen CR
    J Int AIDS Soc; 2017 May; 20(1):21396. PubMed ID: 28530033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a systematic review and meta-analysis.
    Jiang HY; Zhang MN; Chen HJ; Yang Y; Deng M; Ruan B
    Int J Infect Dis; 2014 Aug; 25():130-5. PubMed ID: 24911886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of patient genetics on etonogestrel pharmacokinetics when combined with efavirenz or nevirapine ART.
    Neary M; Chappell CA; Scarsi KK; Nakalema S; Matovu J; Achilles SL; Chen BA; Siccardi M; Owen A; Lamorde M
    J Antimicrob Chemother; 2019 Oct; 74(10):3003-3010. PubMed ID: 31299074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparing the effectiveness of efavirenz and nevirapine for first-line antiretroviral therapy in a South African multicentre cohort.
    Bock P; Fatti G; Grimwood A
    Int Health; 2013 Jun; 5(2):132-8. PubMed ID: 24030113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised non-inferiority trial.
    Bonnet M; Bhatt N; Baudin E; Silva C; Michon C; Taburet AM; Ciaffi L; Sobry A; Bastos R; Nunes E; Rouzioux C; Jani I; Calmy A;
    Lancet Infect Dis; 2013 Apr; 13(4):303-12. PubMed ID: 23433590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis Prevention.
    Podany AT; Bao Y; Swindells S; Chaisson RE; Andersen JW; Mwelase T; Supparatpinyo K; Mohapi L; Gupta A; Benson CA; Kim P; Fletcher CV;
    Clin Infect Dis; 2015 Oct; 61(8):1322-7. PubMed ID: 26082504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.